Mesenchymal stromal cells (MSCs) currently constitute the most frequently used cell type in advanced therapies with different purposes, most of which are related with inflammatory processes. Mesenchymal stromal cells (MSCs) are a heterogeneous population of adherent non-hematopoietic stem cells, with a fusiform appearance, capable of differentiating into bone, adipose and cartilage tissues. During many years, we have worked with MSCs from different sources (fat, bone marrow) and different origins (human, mouse, equine), characterizing them in vitro, studying their immunomodulatory properties and investigating the possible mechanisms of action of MSCs. To test the in vivo efficacy of MSCs, we have developed different mouse models related with complications associated with allogeneic transplants. Another line of study includes the MSC effect on hematopoietic stem cell engraftment in autologous transplants with risks of graft failure. Although the therapeutic efficacy of MSCs has been clearly demonstrated in different disease animal models and in numerous human phase I/II clinical trials, only very few phase III trials using MSCs have demonstrated the expected potential therapeutic benefit. To improve the properties and functional capabilities of MSCs we are developing new therapeutic tools based on gene transfer with lentiviral vectors or with messenger RNAs to increase the therapeutic efficacy of MSCs by improving their ability to migrate to tissues and enhancing their therapeutic effect for their application in different inflammatory and hematological pathologies such as graft-versus-host disease or bone marrow failure associated with autologous transplants in gene therapy protocols.



Rosa M. Yáñez González. PhD

María Fernández García. PhD

Miriam Hernando Rodríguez. PhD


Rosa M. Yáñez González

Rosa M. Yáñez González

Head of Research Area